Coherus BioSciences (NASDAQ:CHRS) is gearing up to announce its quarterly earnings on Thursday, 2025-11-06. Here's a quick overview of what investors should know before the release. Analysts are ...

Investing.com -- Coherus BioSciences Inc (NASDAQ:CHRS) stock tumbled 14.5% in premarket trading on Friday after the oncology company announced the pricing of a public offering of 28.6 million shares ...

Coherus Oncology (CHRS) has priced an underwritten public offering of 28.6M shares at $1.75 per share. The company expects to ...

Coherus BioSciences, Inc. announced the completion of its strategic transformation to focus on innovative oncology during Q2 2025, highlighting encouraging Phase 1b data for CHS-114, an anti-CCR8 ...

Coherus BioSciences CHRS will release its quarterly earnings report on Thursday, 2025-08-07. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Coherus BioSciences to ...

COHERUS BIOSCIENCES ($CHRS) is expected to release its quarterly earnings data on Monday, May 12th after market close, per Finnhub. Analysts are expecting revenue of ...

– Positive CHS-114 (anti-CCR8 antibody) Phase 1b dose expansion study data in patients with head and neck cancer presented at 2025 AACR Annual Meeting – – Additional CHS-114 Phase 1b studies in 2L ...

REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its first quarter 2025 financial results will be released after market ...

On October 27, 2023, the FDA approved LOQTORZI™ (toripalimab-tpzi) in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced ...

Detailed price information for Coherus Oncology Inc (CHRS-Q) from The Globe and Mail including charting and trades.

“2023 will be a year of continued transformation for Coherus with significant value drivers including four anticipated product launches and multiple upcoming clinical catalysts,” said Denny Lanfear, ...

California, USA-based Coherus Oncology has entered into a clinical supply agreement with JUS healthcare giant Johnson & Johnson to evaluate tagmokitug (CHS-114).